专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012131444A1 METHOD AND SYSTEM TO ENHANCE MANAGEMENT CHANNELS 审中-公开
标题翻译：加强管理渠道的方法与制度
公开(公告)号：WO2012131444A1
公开(公告)日：2012-10-04
申请号：PCT/IB2011/053013
申请日：2011-07-07
申请人： TEJAS NETWORKS LIMITED , RAO, Srinivas, , RANKA, Gajendra, Singh
发明人： RAO, Srinivas, , RANKA, Gajendra, Singh
IPC分类号： H04J3/00
CPC分类号： H04J3/02 , H04J3/04 , H04J3/0691 , H04J3/14 , H04J2203/0057 , H04J2203/0089
摘要： Embodiments of the disclosure relate to a method and system for enhancing management channels. The method comprises operating TDM (Time Division Multiplex) clock frequency at a predefined rate higher than operating frequency based on available management channels. Transmitting data on the management channels using the TDM slots of a TDM based controller at a higher frequency rate.
摘要翻译：本公开的实施例涉及用于增强管理信道的方法和系统。该方法包括基于可用管理信道以比工作频率高的预定速率操作TDM（时分多路复用）时钟频率。使用基于TDM的控制器的TDM时隙以更高的频率速率在管理信道上发送数据。

2. 发明申请

WO2009117134A3 AEROSOLIZED GENETIC VACCINES AND METHODS OF USE 审中-公开
公开(公告)号：WO2009117134A3
公开(公告)日：2009-09-24
申请号：PCT/US2009/001754
申请日：2009-03-20
申请人： NATIONAL INSTITUTES OF HEALTH , ROEDERER, Mario , RAO, Srinivas , NABEL, Gary, J. , ANDREWS, Charla, Anne
发明人： ROEDERER, Mario , RAO, Srinivas , NABEL, Gary, J. , ANDREWS, Charla, Anne
IPC分类号： A61K39/04 , A61K39/145 , A61K39/21
摘要： The present invention generally features methods for the mucosal delivery of immunogenic compositions and methods for treating or preventing diseases featuring such immunogenic compositions. In particular embodiments, the immunogenic compositions are genetic vaccines formulated as aerosols.

3. 发明申请

WO2008147843A1 METHODS FOR IMPROVING PHYSICAL FUNCTION IN FIBROMYALGIA 审中-公开
标题翻译：改善纤维肌肉功能的方法
公开(公告)号：WO2008147843A1
公开(公告)日：2008-12-04
申请号：PCT/US2008/064471
申请日：2008-05-22
申请人： CYPRESS BIOSCIENCE, INC. , RAO, Srinivas , GENDREAU, Michael , KRANZLER, Jay
发明人： RAO, Srinivas , GENDREAU, Michael , KRANZLER, Jay
IPC分类号： A61K9/22
CPC分类号： A61K31/165 , A61K31/00 , A61K45/06 , A61K2300/00
摘要： Methods for improving physical function in fibromyalgia syndrome by administering an NSRI such as milnacipran as disclosed. Treatment methods include a 100 mg and 200 mg QD regimen. The treatment regimens may be divided in daily doses, up to four times per day. A second active compound may also be included in the treatment regimen, to treat cognitive dysfunctions associated with fibromyalgia.
摘要翻译：通过施用如所公开的米那普仑等NSRI来改善纤维肌痛综合征的身体功能的方法。治疗方法包括100mg和200mg QD方案。治疗方案可以以每日剂量分开，每天最多四次。治疗方案中还可以包括第二活性化合物，以治疗与纤维肌痛相关的认知功能障碍。

4. 发明申请

WO2008021932A2 MILNACIPRAN FOR THE TREATMENT OF COGNITIVE DYSFUNCTION ASSOCIATED WITH FIBROMYALGIA 审中-公开
标题翻译：治疗与纤维母细胞瘤相关的认知功能障碍的MILNACIPRAN
公开(公告)号：WO2008021932A2
公开(公告)日：2008-02-21
申请号：PCT/US2007075549
申请日：2007-08-09
申请人： CYPRESS BIOSCIENCE INC , GENDREAU MICHAEL R , KRANZLER JAY D , RAO SRINIVAS G
发明人： GENDREAU MICHAEL R , KRANZLER JAY D , RAO SRINIVAS G
IPC分类号： A61K31/165 , A61K31/195 , A61K31/197 , A61K31/4168 , A61K31/428 , A61K31/433 , A61K31/48 , A61K31/485
CPC分类号： A61K31/165 , A61K31/195 , A61K31/197 , A61K31/4168 , A61K31/428 , A61K31/433 , A61K31/48 , A61K31/485 , A61K45/06 , A61K2300/00
摘要： Methods for treating cognitive dysfunction associated with fibromyalgia by administering high-dose milnacipran to a patient suffering from such cognitive dysfunction are provided. Also provided are methods for the long-term treatment of cognitive dysfunction associate with FMS by administering milnacipran to a patient suffering from such cognitive dysfunction.
摘要翻译：提供了通过对患有这种认知功能障碍的患者施用高剂量米那普仑来治疗与纤维肌痛相关的认知功能障碍的方法。还提供了通过对患有这种认知功能障碍的患者施用米那普仑来长期治疗与FMS相关的认知功能障碍的方法。

5. 发明申请

WO2004105690A3 TREATMENT OF CHRONIC PAIN ASSOCIATED WITH DRUG OR RADIATION THERAPY 审中-公开
标题翻译：治疗与药物或放射治疗相关的慢性疼痛
公开(公告)号：WO2004105690A3
公开(公告)日：2005-03-10
申请号：PCT/US2004016101
申请日：2004-05-20
申请人： CYPRESS BIOSCIENCE INC , RAO SRINIVAS G , KRANZLER JAY D
发明人： RAO SRINIVAS G , KRANZLER JAY D
IPC分类号： A61K20060101 , A61K31/137 , A61K31/22 , A61K31/55
CPC分类号： A61K31/22
摘要： Methods for treating chronic widespread pain associated with drug therapy or radiation therapy are described. The method generally involves administering a therapeutically effective amount of a dual or tri reuptake inhibitor of a specific type or a pharmaceutically acceptable salt thereof. Preferably the compound is a non-tricyclic dual reuptake inhibitor. The most preferred compound is milnacipran or a bioequivalent or pharmaceutically acceptable salt thereof. Other preferred compounds are duloxetine and venlafaxine or a bioequivalent or pharmaceutically acceptable salt thereof. In yet another embodiment, a therapeutically effective amount of a non-tricyclic triple reuptake inhibitor ("TRI") compound of a specific type, or a pharmaceutically acceptable salt thereof, is administered. The TRI compounds are characterized by their ability to block the reuptake (and, hence, increase central concentrations of) the three primary brain monoamines: serotonin, noradrenaline, and dopamine.
摘要翻译：描述了治疗与药物治疗或放射治疗相关的慢性广泛疼痛的方法。该方法通常涉及给予治疗有效量的特异型或其可药用盐的双重或三次再摄取抑制剂。优选地，该化合物是非三环双重再摄取抑制剂。最优选的化合物是米那普仑或其生物等效或药学上可接受的盐。其他优选的化合物是度洛西汀和文拉法辛或其生物等效或药学上可接受的盐。在另一个实施方案中，施用治疗有效量的特定类型的非三环三重再摄取抑制剂（“TRI”）化合物或其药学上可接受的盐。 TRI化合物的特征在于其阻断三种主要脑单胺（5-羟色胺，去甲肾上腺素和多巴胺）的再摄取（并因此增加中心浓度）的能力。

6. 发明申请

WO2016118537A1 METHOD AND SYSTEM FOR CREATING SEAMLESS NARRATED VIDEOS USING REAL TIME STREAMING MEDIA 审中-公开
标题翻译：使用实时流媒体创建无缝NARRATED视频的方法和系统
公开(公告)号：WO2016118537A1
公开(公告)日：2016-07-28
申请号：PCT/US2016/013976
申请日：2016-01-19
申请人： RAO, Srinivas
发明人： RAO, Srinivas
IPC分类号： H04N7/173
CPC分类号： H04N21/47205 , G06F3/0482 , G06F9/451 , G06F2203/04803 , H04L65/60 , H04N21/4307 , H04N21/4622 , H04N21/47217 , H04N21/4782 , H04N21/4884
摘要： A computer-implemented method and system for creating a streaming media compilation having time-synchronized annotations. The computer-implemented method includes accessing streaming media from one or more external sources through a browser user interface. Further, the computer-implemented method includes passing a particular Nr8 to two entities to a requesting browser and tagging and annotating the streaming media. Furthermore, the computer-implemented method includes mapping the annotations to a master time-line thereby providing a single seamless video experience of one single media presentation wherein the user performs a desired action, the action includes one of play, pause, seek and scroll. Moreover, the computer-implemented method includes displaying a top panel and a bottom panel to a user through a Nr8 user interface.
摘要翻译：一种用于创建具有时间同步注释的流媒体汇编的计算机实现的方法和系统。计算机实现的方法包括通过浏览器用户界面从一个或多个外部源访问流媒体。此外，计算机实现的方法包括将特定Nr8传递给两个实体到请求浏览器，并标记和注释流媒体。此外，计算机实现的方法包括将注释映射到主时间线，从而提供单个媒体呈现的单个无缝视频体验，其中用户执行期望的动作，该动作包括播放，暂停，寻找和滚动之一。此外，计算机实现的方法包括通过Nr8用户界面向用户显示顶板和底板。

7. 发明申请

WO2009087654A3 ? NOVEL MECHANISM TO ENGAGE GEARS IN MOTION 审中-公开
标题翻译：？在运动中接触齿轮的新机制
公开(公告)号：WO2009087654A3
公开(公告)日：2009-12-03
申请号：PCT/IN2008000702
申请日：2008-10-24
申请人： MAHINDRA AND MAHINDRA , GILL SANJAY , ADIGA GANESH , RAO SRINIVAS K V V , RANADE NITIN SHANKAR
发明人： GILL SANJAY , ADIGA GANESH , RAO SRINIVAS K V V , RANADE NITIN SHANKAR
IPC分类号： G05G5/08
CPC分类号： F16H63/302
摘要： The invention comprises a reverse gear engagement mechanism that engages reverse gear effectively and while minimizing the reverse gear wear and tear and the noise level. It works by reducing the speed of reverse idler gear to a level required for reverse gear engagement, before engaging with the idler fixed gear. The invention can be installed on new and existing automobiles that have manual gearboxes. The mechanism used for the speed reduction comprises specially designed and located friction elements that reduce the speeds of axial and rotational motions of the idler reverse gear. The axial and rotational speeds are reduced to a range where the idler reverse gear engages with the fixed reverse gear smoothly, thereby causing minimal noise and wear and tear of the engaging parts.
摘要翻译：本发明包括倒档接合机构，该倒档接合机构有效地接合倒档并且同时最小化倒档磨损和噪音水平。在与惰轮固定齿轮接合之前，它通过将倒档惰轮的速度降低至倒档接合所需的水平来工作。本发明可以安装在具有手动变速箱的新的和现有的汽车上。用于减速的机构包括专门设计和定位的摩擦元件，其减小惰轮倒档的轴向和旋转运动的速度。轴向转速和转速减小到惰轮倒档齿轮与固定倒档齿轮平滑啮合的范围，由此导致啮合部分的噪音和磨损最小。

8. 发明申请

WO2009092038A8 INFLUENZA DNA VACCINATION AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2009092038A8
公开(公告)日：2009-07-23
申请号：PCT/US2009/031329
申请日：2009-01-16
申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , RAO, Srinivas , NABEL, Gary, J. , YANG, Zih-yong , WEI, Chih-jen , KONG, Wing-pui
发明人： RAO, Srinivas , NABEL, Gary, J. , YANG, Zih-yong , WEI, Chih-jen , KONG, Wing-pui
IPC分类号： A61K39/145
摘要： Sustained outbreaks of highly pathogenic avian influenza (HPAI) H5N1 in avian species increase the risk of reassortment and adaptation to humans. The ability to contain its spread in birds would reduce this threat and help maintain the capacity for egg-based vaccine production. While vaccines offer the potential to control avian disease, a major concern of current vaccines is their inability to protect against evolving avian influenza viruses. DNA vaccines encoding hemagglutinin (HA) proteins from different HPAI H5N1 serotypes protect against homologous and heterologous HPAI H5N1 strain challenge in animals. These vaccines elicit antibodies that neutralize multiple serotypes of HPAI H5N1 when given in combinations containing up to 10 HAs. The response is dose-dependent. The breadth of protection is determined by the choice of the influenza virus HA in the vaccine. Monovalent and trivalent HA immunogens and/or vaccines conferred complete protection in mice against lethal H5N1 A/Vietnam/ 1203/2004 challenge 68 weeks after vaccination. In chickens, complete protection was conferred against heterologous strains of HPAI H5N1 after vaccination with a trivalent H5 serotype DNA vaccine with doses as low as 5 μg DNA given twice either by intramuscular needle injection or with a needle-free device.

9. 发明申请

WO2009092038A1 INFLUENZ DNA VACCINATION AND METHODS OF USE THEREOF 审中-公开
标题翻译： INFLUENZ DNA疫苗及其使用方法
公开(公告)号：WO2009092038A1
公开(公告)日：2009-07-23
申请号：PCT/US2009031329
申请日：2009-01-16
申请人： US GOV HEALTH & HUMAN SERV , RAO SRINIVAS , NABEL GARY J , YANG ZIH-YONG , WEI CHIH-JEN , KONG WING-PUI
发明人： RAO SRINIVAS , NABEL GARY J , YANG ZIH-YONG , WEI CHIH-JEN , KONG WING-PUI
IPC分类号： A61K39/145
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/53 , A61K2039/54 , A61K2039/58 , A61K2039/70 , C07K14/005 , C12N2760/16122 , C12N2760/16134
摘要： Sustained outbreaks of highly pathogenic avian influenza (HPAI) H5N1 in avian species increase the risk of reassortment and adaptation to humans. The ability to contain its spread in birds would reduce this threat and help maintain the capacity for egg-based vaccine production. While vaccines offer the potential to control avian disease, a major concern of current vaccines is their inability to protect against evolving avian influenza viruses. DNA vaccines encoding hemagglutinin (HA) proteins from different HPAI H5N1 serotypes protect against homologous and heterologous HPAI H5N1 strain challenge in animals. These vaccines elicit antibodies that neutralize multiple serotypes of HPAI H5N1 when given in combinations containing up to 10 HAs. The response is dose-dependent. The breadth of protection is determined by the choice of the influenza virus HA in the vaccine. Monovalent and trivalent HA immunogens and/or vaccines conferred complete protection in mice against lethal H5N1 A/Vietnam/ 1203/2004 challenge 68 weeks after vaccination. In chickens, complete protection was conferred against heterologous strains of HPAI H5N1 after vaccination with a trivalent H5 serotype DNA vaccine with doses as low as 5 µg DNA given twice either by intramuscular needle injection or with a needle-free device.
摘要翻译：高致病性禽流感（HPAI）H5N1在禽类物种中的持续爆发增加了重配和适应人类的风险。控制其在鸟类中传播的能力将减少这种威胁，并有助于维持基于蛋的疫苗生产的能力。虽然疫苗具有控制禽流感病毒的潜力，但目前疫苗的主要问题是其无法防止禽流感病毒进化。编码来自不同HPAI H5N1血清型的血凝素（HA）蛋白质的DNA疫苗保护动物免受同源和异源HPAI H5N1毒株攻击。当以最多10HA的组合给予时，这些疫苗引发中和多种血清型的HPAI H5N1的抗体。反应是剂量依赖性的。保护的广度由疫苗中流感病毒HA的选择决定。疫苗接种后68周，单价和三价HA免疫原和/或疫苗在小鼠中完全保护免于致死的H5N1 A /越南/ 1203/2004攻击。在鸡中，用三价H5血清型DNA疫苗接种后，通过肌内注射或无针装置给予两次，剂量低至5μg的DNA，对抗HPAI H5N1的异源菌株进行完全保护。

10. 发明申请

WO2009023820A1 IMPROVING THE TOLERABILITY OF A SEROTONIN ANTAGONIST AND A NSRI, A SNRI OR A RIMA BY USING THEM IN COMBINATION 审中-公开
标题翻译：通过使用它们组合，改善丝氨酸拮抗剂和NSRI，SNRI或RIMA的耐受性
公开(公告)号：WO2009023820A1
公开(公告)日：2009-02-19
申请号：PCT/US2008/073281
申请日：2008-08-15
申请人： CYPRESS BIOSCIENCES, INC. , RAO, Srinivas , KRANZLER, Jay, D. , ANDERSON, Jeffery, J.
发明人： RAO, Srinivas , KRANZLER, Jay, D. , ANDERSON, Jeffery, J.
IPC分类号： A01N43/00 , A01N43/62 , A61K31/53
CPC分类号： A61K31/381 , A61K31/165 , A61K31/55 , A61K2300/00
摘要： Provided are combinations of pharmaceutical agents capable of eliciting a therapeutic effect. A first therapeutic agent in the combination has 5HT 2 /5HT 3 antagonist and alpha-2 antagonist activity. A second therapeutic agent possesses both serotonin reuptake inhibitory activity and norepinephrine reuptake inhibitory activity or is a reversible inhibitor of monoamine oxidase A (REVIA). In some embodiments, a combination of a first therapeutic agent and a second therapeutic agent results in reduction in one or deleterious side effects associated with the first therapeutic agent, the second therapeutic agent or both. Also provided are methods of treatment employing a first therapeutic agent and a second therapeutic agent. Also provided are kits containing a first therapeutic agent, a second therapeutic agent and instructions for administering the first therapeutic agent and the second therapeutic agent.
摘要翻译：提供能够引起治疗效果的药剂的组合。该组合中的第一种治疗剂具有5HT2 / 5HT3拮抗剂和α-2拮抗剂活性。第二种治疗剂具有5-羟色胺再摄取抑制活性和去甲肾上腺素再摄取抑制活性，或者是单胺氧化酶A（REVIA）的可逆抑制剂。在一些实施方案中，第一治疗剂和第二治疗剂的组合导致减少与第一治疗剂，第二治疗剂或两者相关的一种或有害副作用。还提供使用第一治疗剂和第二治疗剂的治疗方法。还提供了含有第一治疗剂，第二治疗剂和用于施用第一治疗剂和第二治疗剂的说明书的试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式